SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-016835
Filing Date
2023-05-09
Accepted
2023-05-09 16:22:07
Documents
64
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20230331.htm   iXBRL 10-Q 1370897
2 EX-31.1 mrtx-2023331xex311.htm EX-31.1 13772
3 EX-31.2 mrtx-2023331xex312.htm EX-31.2 14673
4 EX-32.1 mrtx-2023331xex321.htm EX-32.1 7772
  Complete submission text file 0001628280-23-016835.txt   5831084

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20230331.xsd EX-101.SCH 40324
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20230331_cal.xml EX-101.CAL 69747
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20230331_def.xml EX-101.DEF 160526
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20230331_lab.xml EX-101.LAB 476695
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20230331_pre.xml EX-101.PRE 297923
58 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20230331_htm.xml XML 908745
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 23902409
SIC: 2834 Pharmaceutical Preparations